2 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Terminated 1 |
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
Follow MCLA-129: new trials by email Literature Review of MCLA-129 trials Research Report on MCLA-129
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. MCLA-129, Ensartinib - Solid Advanced Tumor | Phase 1 / Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 164 | 2026-01-31 | 2026-03-04 |
| Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors MCLA-129 - Solid Tumor, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 400 | 2021-09-24 | 2026-02-10 |
| Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination MCLA-129, Osimertinib, Chemotherapy - Non-Small Cell Lung Cancer Metastatic, Gastric Cancer | Phase 1 / Phase 2 | Terminated | Merus B.V. | 194 | 2021-04-28 | 2026-10-26 |
Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Squamous Cell Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
Betta Pharmaceuticals Co., Ltd. (2) · Merus B.V. (1)
China (2) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · United States (1)
Jie Wang, PhD (1)